Serina Therapeutics
Serina Therapeutics is dedicated to pioneering bold new science in polymer therapeutics and drug delivery platforms. Their mission is to develop innovative treatments for neurological diseases and other indications using their proprietary POZ platform technology, which enables programmable, targeted delivery of small molecules, proteins, and other therapeutic agents. They focus on addressing unmet medical needs, particularly in CNS disorders like Parkinson's disease, and collaborate with partners to advance RNA medicines, cancer immunotherapy, and gene therapy.
Industries
Nr. of Employees
small (1-50)
Serina Therapeutics
Huntsville, Alabama, United States, North America
Products
Poly(2-oxazoline)-based polymer-drug conjugation platform
A synthetic, water-soluble polymer platform enabling covalent attachment of therapeutic payloads with controlled loading and programmable release for extended systemic exposure.
Long-acting apomorphine formulation for advanced Parkinson’s disease
A polymer-conjugated apomorphine candidate designed to provide continuous dopaminergic stimulation via periodic subcutaneous dosing without an infusion pump or continuous tubing.
Platform partner programs: LNP and ADC-enabled formulations
Collaborative development programs applying the polymer platform to lipid nanoparticle systems for RNA therapeutics and to antibody conjugation strategies for oncology payload delivery.
Poly(2-oxazoline)-based polymer-drug conjugation platform
A synthetic, water-soluble polymer platform enabling covalent attachment of therapeutic payloads with controlled loading and programmable release for extended systemic exposure.
Long-acting apomorphine formulation for advanced Parkinson’s disease
A polymer-conjugated apomorphine candidate designed to provide continuous dopaminergic stimulation via periodic subcutaneous dosing without an infusion pump or continuous tubing.
Platform partner programs: LNP and ADC-enabled formulations
Collaborative development programs applying the polymer platform to lipid nanoparticle systems for RNA therapeutics and to antibody conjugation strategies for oncology payload delivery.
Services
Collaborative platform R&D partnerships
Partnering with pharmaceutical and biotechnology companies to apply polymer-drug conjugation and LNP approaches to partner drug candidates across small molecules, RNA therapeutics, and ADCs.
CMC and formulation development services
Phase-appropriate drug product development, process chemistry oversight, and preparation for product validation and pre-approval inspection readiness.
Collaborative platform R&D partnerships
Partnering with pharmaceutical and biotechnology companies to apply polymer-drug conjugation and LNP approaches to partner drug candidates across small molecules, RNA therapeutics, and ADCs.
CMC and formulation development services
Phase-appropriate drug product development, process chemistry oversight, and preparation for product validation and pre-approval inspection readiness.
Expertise Areas
- Polymer therapeutics
- Long-acting parenteral drug delivery
- CMC and formulation development
- Preclinical and IND-enabling development
Key Technologies
- Poly(2-oxazoline) polymer therapeutics
- Polymer-drug conjugation
- Metal-catalyzed click chemistry
- Programmable release kinetics